Nordic Life Science 1
FINANCING // INVESTOR INTERVIEW “Eventually condi
tions will improve, and this may be just around the corner!” Personalized medicine, weight loss remedies and new treatments for widespread ailments are among the rising areas of high interest in the biotechnology and therapeutic arenas, according to Executive Chairman of Flerie Invest, Thomas Eldered. T E X T B Y EL L EN R . DEL I S I O T HOMAS ELDERED talked with Nordic Life Science about the Nordic and global life science financial landscapes and Flerie’s role in funding new ventures. What do you view as the hot areas in the technologies/therapeutic fields? “We are seeing some amazing and promising results in personalized medicine, and we expect that to be a very hot area going forward. Treatments for diabetes, both type 1 and 2, are also in focus and obviously the superhot obesity space where we believe there is room for more novel therapies with new mechanisms of action.” “Oncology products with significantly better treatment outcomes than the current gold standard are also of high interest. We shouldn't forget huge areas like heart failure, where there is still no good treatment. Innovative new products (in this area) will attract a lot of interest.” Who do you think will receive venture capital funds and other financing and who will not? “In general, innovative products in areas of high medical need. The risk-averse conditions will remain, meaning that projects that manage to combine risk NORDICLIFESCIENCE.ORG | 41